Lancashire and South Cumbria
Formulary
Formulary
10 Musculoskeletal and joint diseases
10-02-02 Skeletal muscle relaxants
| Cannabis extract Sativex® |
|
Formulary
|
Oromucosal spray cannabidiol 2.5mg per dose, Dronabinol 2.7mg per dose
|
 NICE NG144: Cannabis-based medicinal products |
|
for Refractory neuropathic pain.| Diazepam |
|
Formulary
|
Tablets 2mg, 5mg, 10mg |
|
MHRA: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression |
|
| Mexiletine hydrochloride Namuscla® |
|
Formulary
|
Capsules 167mg |
|
NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders |
|
Links
- Cochrane review of the evidence
EMSCG Commissioning policy for Intrathecal Baclofen (ITB)- Lancashire and South Cumbria Infant Feeding Network - Diagnosis and Management of Milk Allergy and Intolerance Guideline
- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update Nov 2017: Quinine: reminder of dose-dependent QT-prolonging effects; updated medicine interactions
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression
- MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
- MHRA: Nusinersen (Spinraza▼): reports of communicating hydrocephalus; discuss symptoms with patients and carers and investigate urgently
- MHRA: Quinine: not to be used routinely for nocturnal leg cramps
- MHRA: Quinine: reminder of dose-dependent QT-prolonging effects; updated medicine interactions
- NHSE: Steroid Emergency Card to support early recognition and treatment of adrenal crisis in adults
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE HST15: Onasemnogene abeparvovec for treating spinal muscular atrophy
- NICE HST15: Onasemnogene abeparvovec for treating spinal muscular atrophy
- NICE HST22:Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
- NICE HST24: Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy
- NICE HST24: Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE NG144: Cannabis-based medicinal products
- NICE NG144:Cannabis-based medicinal products
- NICE NST22 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
- NICE TA1031: Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over
- NICE TA588: Nusinersen for treating spinal muscular atrophy
- NICE TA588: Nusinersen for treating spinal muscular atrophy
- NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
- NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
- NICE TA755: Risdiplam for treating spinal muscular atrophy
- NICE TA755:Risdiplam for treating spinal muscular atrophy